American Journal Geriatric Pharmacotherapy最新文献

{"title":"Role of the Pharmacist on a General Medicine Acute Care for the Elderly Unit","authors":"Timothy Reilly PharmD, BCPS, CGP, FASCP ,&nbsp;David Barile MD ,&nbsp;Stanley Reuben RPh, MBA","doi":"10.1016/j.amjopharm.2012.02.002","DOIUrl":"10.1016/j.amjopharm.2012.02.002","url":null,"abstract":"<div><h3>Background</h3><p>The prevalence of prescription medication use increases with age, and older adults are at increased risk of harm from medication use.</p></div><div><h3>Objective</h3><p>To describe the role of a pharmacist on a General Medicine Acute Care of the Elderly (GM-ACE) Unit.</p></div><div><h3>Methods</h3><p>A job description was prepared, and a clinical pharmacist specializing in internal medicine<span><span><span><span> was re-assigned to participate in multidisciplinary rounds on the ACE unit twice weekly and to work with a unit-based pharmacist assigned to multiple units. The clinical pharmacist also provided formal education on geriatric </span>pharmacotherapy for other health care providers. Interventions were defined as changes in the </span>medical record and provision of </span>drug information. Interventions were tracked with an existing form and sorted by category. Data on interventions were presented to the pharmacy and therapeutics committee routinely.</span></p></div><div><h3>Results</h3><p>After 3 months, the clinical pharmacist accomplished 76 interventions in the areas of agent selection, dose optimization, addition of therapy, deletion of therapy, medication reconciliation, intravenous to oral conversion, technology improvements, and drug information/patient education.</p></div><div><h3>Conclusion</h3><p>Expanding the role of the pharmacist in a GM-ACE unit has improved the medication use process in a high-risk population through improvements in medication overuse, medication underuse, dosing, medication reconciliation, patient education, and health care provider education.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 2","pages":"Pages 95-100"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2012.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30503864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applicability of an Adapted Medication Appropriateness Index for Detection of Drug-Related Problems in Geriatric Inpatients","authors":"Annemie Somers PharmD ,&nbsp;Louise Mallet PharmD ,&nbsp;Tischa van der Cammen MD, PhD ,&nbsp;Hugo Robays PharmD ,&nbsp;Mirko Petrovic MD, PhD","doi":"10.1016/j.amjopharm.2012.01.003","DOIUrl":"10.1016/j.amjopharm.2012.01.003","url":null,"abstract":"<div><h3>Background</h3><p>High drug consumption by older patients and the presence of many drug-related problems require careful assessment of drug therapy, for which a structured approach is recommended.</p></div><div><h3>Objective</h3><p>The purpose of our study was to evaluate the applicability of an adapted version of the Medication Appropriateness Index<span> (MAI) in 50 geriatric inpatients at the time of admission.</span></p></div><div><h3>Methods</h3><p>We reviewed, for 432 prescribed drugs, indication, right choice, dosage, directions, drug–disease interactions, drug–drug interactions, and duration of therapy. In addition, adverse drug reactions were evaluated, resulting in 8 questions per drug. MAI scores were attributed independently by a geriatrician and by a clinical pharmacist, and differences between them were assessed. Furthermore, the relationship between MAI score and drug-related hospital admission was explored.</p></div><div><h3>Results</h3><p><span>Mean summed MAI scores of 13.7 according to the geriatrician and 13.6 according to the pharmacist were obtained. The highest scores were found for drugs for the central nervous and the urinary tract system; the highest scores per question were detected for right choice, adverse drug reactions, and drug–drug interactions. A good agreement between the scores of the geriatrician and the pharmacist was found: intraclass correlation coefficient was 0.91 and overall κ value was 0.71. A significantly higher MAI score was found for drug-related hospital admissions (</span><em>P</em> = 0.04 for the geriatrician and <em>P =</em> 0.03 for the pharmacist).</p></div><div><h3>Conclusions</h3><p>This adapted MAI score seems useful for detection of drug-related problems in geriatric inpatients and reliable with a low inter-rater variability and positive correlation between high score and drug-related hospital admission. We consider further application of the adapted MAI for teaching and training of clinical pharmacists, and as a systematic approach for detection of drug-related problems by the clinical pharmacists in our hospital.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 2","pages":"Pages 101-109"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2012.01.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30436291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on the New American Geriatric Society Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","authors":"Zachary A. Marcum PharmD, MS ,&nbsp;Joseph T. Hanlon PharmD, MS","doi":"10.1016/j.amjopharm.2012.03.002","DOIUrl":"10.1016/j.amjopharm.2012.03.002","url":null,"abstract":"","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 2","pages":"Pages 151-159"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2012.03.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30558051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Related Changes in Antidepressant Pharmacokinetics and Potential Drug-Drug Interactions: A Comparison of Evidence-Based Literature and Package Insert Information","authors":"Richard D. Boyce PhD ,&nbsp;Steven M. Handler MD, PhD ,&nbsp;Jordan F. Karp MD ,&nbsp;Joseph T. Hanlon PharmD, MS","doi":"10.1016/j.amjopharm.2012.01.001","DOIUrl":"10.1016/j.amjopharm.2012.01.001","url":null,"abstract":"<div><h3>Background</h3><p>Antidepressants are among the most commonly prescribed psychotropic agents<span> for older patients. Little is known about the best source of pharmacotherapy information to consult about key factors necessary to safely prescribe these medications to older patients.</span></p></div><div><h3>Objective</h3><p>The objective of this study was to synthesize and contrast information in the package insert (PI) with information found in the scientific literature about age-related changes of antidepressants in systemic clearance and potential pharmacokinetic drug–drug interactions (DDIs).</p></div><div><h3>Methods</h3><p>A comprehensive search of two databases (MEDLINE and EMBASE from January 1, 1975 to September 30, 2011) with the use of a combination of search terms (<em>antidepressants</em>, <em>pharmacokinetics</em>, and <span><em>drug</em><em> interactions</em></span><span>) was conducted to identify relevant English language articles. This information was independently reviewed by two researchers and synthesized into tables. These same two researchers examined the most up-to-date PIs for the 26 agents available at the time of the study to abstract quantitative information about age-related decline in systemic clearance and potential DDIs<span>. The agreement between the two information sources was tested with κ statistics.</span></span></p></div><div><h3>Results</h3><p>The literature reported age-related clearance changes for 13 antidepressants, whereas the PIs only had evidence about 4 antidepressants (κ &lt; 0.4). Similarly, the literature identified 45 medications that could potentially interact with a specific antidepressant, whereas the PIs only provided evidence about 12 potential medication–antidepressant DDIs (κ &lt; 0.4).</p></div><div><h3>Conclusion</h3><p>The evidence-based literature compared with PIs is the most complete pharmacotherapy information source about both age-related clearance changes and pharmacokinetic DDIs with antidepressants. Future rigorously designed observational studies are needed to examine the combined risk of antidepressants with age-related decline in clearance and potential DDIs on important health outcomes such as falls and fractures in older patients.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 2","pages":"Pages 139-150"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2012.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30420435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability of Topical Diclofenac Sodium 1% Gel for Osteoarthritis in Seniors and Patients With Comorbidities","authors":"Herbert S.B. Baraf MD ,&nbsp;Morris S. Gold ScD ,&nbsp;Richard A. Petruschke PharmD ,&nbsp;Matthew S. Wieman MD","doi":"10.1016/j.amjopharm.2011.12.002","DOIUrl":"10.1016/j.amjopharm.2011.12.002","url":null,"abstract":"<div><h3>Background</h3><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a dose-related risk of cardiovascular, renal, and gastrointestinal adverse events (AEs). Topical NSAIDs produce lower systemic NSAID exposure compared with oral NSAIDs, offering potential benefits.</p></div><div><h3>Objective</h3><p>To evaluate the safety of topical diclofenac sodium 1% gel (DSG) for knee and hand osteoarthritis (OA) in older and younger patients and in patients<span> with versus without comorbid hypertension, type 2 diabetes, or cerebrovascular or cardiovascular disease.</span></p></div><div><h3>Methods</h3><p>Post hoc analysis<span> of pooled data from 5 randomized, double-blind, placebo-controlled trials involving 1426 patients (aged ≥35 years) with mild to moderate OA of the knee and 783 patients (aged ≥40 years) with mild to moderate OA of the hand. Patients applied 4 g of DSG or vehicle to affected knees QID for 12 weeks or 2 g of DSG or vehicle to affected hands QID for 8 weeks.</span></p></div><div><h3>Results</h3><p><span>In patients with knee OA, the percentage with ≥1 adverse event was similar in patients aged &lt;65 years (56.6%) versus ≥65 years (55.8%) and was similar in patients with versus without comorbid hypertension (53.4% vs 59.0%, respectively), type 2 diabetes mellitus (50.0% vs 57.2%), or cerebrovascular or cardiovascular disease (53.8% vs 56.5%). In patients with hand OA, the percentage with ≥1 AE was similar in patients aged ≥65 years (42.7%) versus &lt;65 years (39.1%) and was similar in patients with versus without hypertension (39.6% vs 41.7%, respectively), lower in patients with versus without type 2 diabetes mellitus (28.0% vs 41.6%), and higher in patients with versus without cerebrovascular or cardiovascular disease (48.5% vs 39.2%). Gastrointestinal, cardiovascular, and renal AEs were rare and did not differ according to age or comorbidity. </span>Application site reactions were the primary cause for the greater frequency of AEs with DSG versus vehicle.</p></div><div><h3>Conclusion</h3><p>The similar and low rates of AEs in DSG-treated patients aged ≥65 years and &lt;65 years and in those with and without comorbid hypertension, type 2 diabetes, or cerebrovascular or cardiovascular disease suggest that DSG treatment is generally well tolerated.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 1","pages":"Pages 47-60"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.12.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30403939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsideration of Key Articles Regarding Medication-Related Problems in Older Adults from 2011","authors":"Carolyn T. Thorpe PhD, MPH ,&nbsp;Holly C. Lassila DrPH ,&nbsp;Christine K. O'Neil PharmD ,&nbsp;Joshua M. Thorpe PhD, MPH ,&nbsp;Joseph T. Hanlon PharmD, MS ,&nbsp;Robert L. Maher Jr PharmD","doi":"10.1016/j.amjopharm.2012.01.004","DOIUrl":"10.1016/j.amjopharm.2012.01.004","url":null,"abstract":"","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 1","pages":"Pages 2-13"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2012.01.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30456270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Warfarin Use in Nursing Home Residents: Results from the 2004 National Nursing Home Survey","authors":"Parinaz K. Ghaswalla PhD,&nbsp;Spencer E. Harpe PharmD, PhD, MPH,&nbsp;Patricia W. Slattum PharmD, PhD","doi":"10.1016/j.amjopharm.2011.12.001","DOIUrl":"10.1016/j.amjopharm.2011.12.001","url":null,"abstract":"<div><h3>Background</h3><p><span>Practice guidelines recommend anticoagulation therapy with warfarin for stroke prevention </span>in patients<span> with atrial fibrillation (AF). Despite this, warfarin is underused in older adults.</span></p></div><div><h3>Objective</h3><p>The purpose of this study was to determine the prevalence of AF in nursing home (NH) residents and the use of warfarin or other antiplatelet medications in NH residents with AF who have indications for and no contraindications against warfarin use. The secondary objective was to determine the factors associated with warfarin use in NH residents with AF.</p></div><div><h3>Methods</h3><p>Cross-sectional analysis of prescription and resident data files from the 2004 National Nursing Home Survey was performed. Residents with a diagnosis of AF were identified using <span><em>International Classification of Diseases</em><em>, Ninth Revision, Clinical Modification</em></span> (ICD-9-CM) codes, and prescriptions of warfarin and antiplatelet medications were identified using Long-Term Care Drug Database System (LTCDDS) codes. Resident characteristics, stroke risk factors, and potential bleeding risk factors significant at <em>P</em> &lt; 0.10 in χ²<span> analyses were entered in the final multiple logistic regression model to determine the factors associated with warfarin use.</span></p></div><div><h3>Results</h3><p><span>From 13,507 NH residents, 1904 (14%) had a diagnosis of AF and 1767 (13%) had a diagnosis of AF with indications for and no contraindications against warfarin use. Of these 1767 residents, 537 (30%) were prescribed warfarin, and of the remaining 1230 residents who were not prescribed warfarin, 283 (23%) received either aspirin<span><span><span> or clopidogrel. Thus, of 1767 residents with AF, with indications for and no contraindications to warfarin use, 947 (54%) residents did not receive any </span>antithrombotic therapy in the form of warfarin, aspirin, clopidogrel, or a combination of these medications. Factors that were significantly associated with increased odds of receiving warfarin were </span>congestive heart failure<span><span><span>, previous stroke or transient ischemic attack<span>, deep vein thrombosis or peripheral </span></span>embolus, </span>valvular heart disease, and total number of medications ≥6. Factors that were significantly associated with reduced odds of receiving warfarin were nonwhite race, history of </span></span></span>gastrointestinal bleeding, and use of antiplatelets (ie, clopidogrel).</p></div><div><h3>Conclusions</h3><p>AF is common in NH residents, and more than half of the residents with AF who had indications for and no contraindications against warfarin use were not prescribed either warfarin or antiplatelets, such as aspirin or clopidogrel, suggesting that antithrombotic therapy may be underused in NH residents with AF.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 1","pages":"Pages 25-36.e2"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30371639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clostridium Difficile Infection in Older Adults: A Review and Update on Its Management","authors":"Vicki R. Kee PharmD, BCPS","doi":"10.1016/j.amjopharm.2011.12.004","DOIUrl":"10.1016/j.amjopharm.2011.12.004","url":null,"abstract":"<div><h3>Background</h3><p><span><em>Clostridium difficile</em></span> is a main cause of health care-associated infections. The incidence and severity have been increasing. Elderly persons are at an increased risk of morbidity and mortality from <em>C. difficile</em><span> infection (CDI). Relatively few advances have been made in the treatment of CDI since it was first identified as a cause of antibiotic-associated diarrhea more than 30 years ago.</span></p></div><div><h3>Objective</h3><p>This article reviews CDI and provides an update on its treatment, including recently published clinical practice guidelines and the recently approved drug<span>, fidaxomicin.</span></p></div><div><h3>Methods</h3><p>English-language literature was identified through a search of PubMed (1966–October 2011), Iowa Drug Information Service (1966–October 2011), and International Pharmaceutical Abstracts (1970–October 2011). Key search terms included <em>Clostridium difficile</em>, <span><em>Clostridium infections</em></span>, <span><em>pseudomembranous colitis</em></span>, <em>antibiotic-associated diarrhea</em>, <em>Clostridium difficile-associated diarrhea</em>, <span><em>elderly, </em><em>geriatric</em><em>, epidemiology</em></span>, <em>microbiology</em>, <em>diagnosis</em>, <em>risk factors</em>, <em>treatment</em>, <span><span><em>drug therapy, </em><em>vancomycin</em><em>, </em></span><em>metronidazole</em><em>,</em></span> and <em>fidaxomicin</em>.</p></div><div><h3>Results</h3><p>Metronidazole and vancomycin remain the mainstays of CDI treatment. Current guidelines recommend oral metronidazole for initial mild to moderate episodes or first recurrence. Oral vancomycin is recommended for initial severe episodes, or first or second recurrence. Fidaxomicin was approved in 2011 for treatment of CDI, but its place in therapy has yet to be determined. Other antibiotics have been used with variable success. <span><em>Saccharomyces boulardii</em></span><span><span><span> is the only probiotic that has shown efficacy in CDI. </span>Fecal transplants<span> have been used successfully in some patients, but randomized studies are needed. Immune therapy<span> with a vaccine and monoclonal antibodies is being studied in </span></span></span>clinical trials.</span></p></div><div><h3>Conclusions</h3><p>Treatment of CDI is challenging due to the limited number of drugs that have proven to be effective, concerns about antibiotic resistance, and recurring disease. The recent approval of fidaxomicin provides a new alternative. Immune therapy will likely play a greater role in the future.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 1","pages":"Pages 14-24"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.12.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30399225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure","authors":"Gail B. Rattinger PharmD, PhD ,&nbsp;Sarah K. Dutcher BS ,&nbsp;Pankdeep T. Chhabra MBBS, MPH ,&nbsp;Christine S. Franey MPH ,&nbsp;Linda Simoni-Wastila BSPharm, PhD ,&nbsp;Stephen S. Gottlieb MD ,&nbsp;Bruce Stuart PhD ,&nbsp;Ilene H. Zuckerman PharmD, PhD","doi":"10.1016/j.amjopharm.2011.11.003","DOIUrl":"10.1016/j.amjopharm.2011.11.003","url":null,"abstract":"<div><h3>Background</h3><p>Alzheimer's disease and related disorders (ADRD) are prevalent in older adults, increase the costs of chronic heart failure (CHF) management, and may be associated with undertreatment of cardiovascular disease.</p></div><div><h3>Objective</h3><p>The purpose of our study was to determine the relationship between comorbid ADRD and CHF medication use and adherence among Medicare beneficiaries with CHF.</p></div><div><h3>Methods</h3><p>This 2-year (1/1/2006–12/31/2007) cross-sectional study used data from the Chronic Condition Data Warehouse of the Centers for Medicare and Medicaid Services. Medicare beneficiaries with evidence of CHF who had systolic dysfunction and Medicare Parts A, B, and D coverage during the entire study period were included. ADRD was identified based on diagnostic codes using the Chronic Condition Data Warehouse algorithm. CHF evidence-based medications (EBMs) were selected based on published guidelines: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, selected β-blockers, aldosterone antagonists, and selected vasodilators. Measures of EBMs included a binary indicator of EBM use and medication possession ratio among users.</p></div><div><h3>Results</h3><p>Of 9827 beneficiaries with CHF and systolic dysfunction, 24.2% had a diagnosis of ADRD. Beneficiaries with ADRD were older (80.8 vs 73.6 years; <em>P</em> &lt; 0.0001) and more likely to be female (69.3% vs 58.1%; <em>P</em> &lt; 0.0001). Overall EBM use was lower in patients with CHF and ADRD compared with patients with CHF but no ADRD (85.3% vs 91.2%; <em>P</em> &lt; 0.0001). Lower use among those with ADRD was consistent across all EBM classes except vasodilators. Among beneficiaries receiving EBM, those with ADRD had a slightly higher mean medication possession ratio for EBM compared with those without ADRD (0.86 vs 0.84; <em>P</em> = 0.0001).</p></div><div><h3>Conclusions</h3><p>EBM medication adherence was high in this population, regardless of ADRD status. However, patients with ADRD had lower EBM use compared with those without ADRD. Low use of specific EBM medications such as β-blockers was found in both groups. Therefore, interventions targeting increased treatment with specific EBMs for CHF, even among patients with ADRD, may be of benefit and could help reduce CHF-related hospitalizations.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 1","pages":"Pages 69-80"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30403941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Goodbyes, Hellos, and Changes","authors":"Kenneth E. Schmader MD (Co-Editor-in-Chief),&nbsp;Joseph T. Hanlon PharmD, MS (Co-Editor-in-Chief)","doi":"10.1016/j.amjopharm.2012.01.005","DOIUrl":"10.1016/j.amjopharm.2012.01.005","url":null,"abstract":"","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"10 1","pages":"Page 1"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2012.01.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"101842108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}